# **Special Issue**

# Gallium 68 Radiochemistry and Labelling Strategies

# Message from the Guest Editors

Gallium-68 (68Ga) has proven to be an essential radionuclide for the fundamental biological studies, development of radiopharmaceuticals for clinical use, and drug development due to its favorable physical and chemical properties as well as ready availability from a generator system. The interest in 68Ga has increased tremendously in the recent decade as a result of wide clinical applications in combination with positron emission tomography (PET) and its connection to the subsequent radiotherapy in the context of (radio)theranostics. The crucial advantages of 68Ga are its availability from a 68Ge/68Ga generator and its labelling chemistry amenable to the automation and kittype preparation. Moreover, it can nowadays also be produced with a cyclotron using solid and liquid targets. This Special Issue will focus on the development of 68Ga radiopharmaceuticals and their applications. The subject may range from radioactive isotope production, labeling chemistry and quality control to preclinical evaluation and clinical trials and clinical routine application. The (radio)theranostic and pharmacokinetic modelling studies are also of strong interest.

## **Guest Editors**

Dr. Giuseppe Carlucci

Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095, USA

Dr. Irina Velikyan

Department of Surgical Science, Uppsala University, 751 85 Uppsala, Sweden

## Deadline for manuscript submissions

closed (20 February 2024)



# **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/160359

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





# **Pharmaceutica**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



# **About the Journal**

# Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

#### Editor-in-Chief

#### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

## **Author Benefits**

## Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

